Gemzar



Indications and Reactions:

Role Indications Reactions
Primary
Pancreatic Carcinoma 23.0%
Non-small Cell Lung Cancer 10.5%
Pancreatic Carcinoma Stage Iv 6.6%
Prophylaxis 6.6%
Breast Cancer Metastatic 5.5%
Bile Duct Cancer 5.0%
Lung Neoplasm Malignant 4.9%
Bladder Cancer 4.3%
Ovarian Cancer 4.0%
Hypertension 3.6%
Pancreatic Carcinoma Metastatic 3.6%
Pain 3.6%
Prophylaxis Of Nausea And Vomiting 3.2%
Adenocarcinoma Pancreas 2.9%
Breast Cancer 2.7%
Constipation 2.1%
Cancer Pain 2.0%
Premedication 1.9%
Transitional Cell Carcinoma 1.9%
Ovarian Cancer Recurrent 1.9%
Death 16.2%
White Blood Cell Count Decreased 9.5%
Thrombocytopenia 8.3%
Malignant Neoplasm Progression 7.9%
Vomiting 7.5%
Pyrexia 6.1%
Interstitial Lung Disease 4.9%
Platelet Count Decreased 3.6%
Neoplasm Progression 3.6%
Pleural Effusion 3.6%
Lung Disorder 3.2%
Pneumonia 3.2%
Off Label Use 3.1%
Renal Failure 3.0%
Pulmonary Embolism 3.0%
Thrombotic Thrombocytopenic Purpura 2.8%
Sepsis 2.8%
Thrombotic Microangiopathy 2.8%
Haematotoxicity 2.7%
Pulmonary Toxicity 2.3%
Secondary
Drug Use For Unknown Indication 16.3%
Product Used For Unknown Indication 14.6%
Non-small Cell Lung Cancer 14.4%
Pancreatic Carcinoma 8.7%
Prophylaxis 7.4%
Breast Cancer Metastatic 4.2%
Pancreatic Carcinoma Stage Iv 4.1%
Breast Cancer 4.1%
Hypertension 3.0%
Adenocarcinoma Pancreas 2.9%
Premedication 2.8%
Pain 2.3%
Lung Neoplasm Malignant 2.3%
Bile Duct Cancer 2.1%
Pancreatic Carcinoma Metastatic 2.0%
Prophylaxis Of Nausea And Vomiting 2.0%
Lung Adenocarcinoma 1.8%
Constipation 1.8%
Cancer Pain 1.7%
Ovarian Cancer 1.5%
White Blood Cell Count Decreased 15.0%
Thrombocytopenia 10.7%
Vomiting 10.1%
Interstitial Lung Disease 7.1%
Malignant Neoplasm Progression 6.7%
Pyrexia 6.0%
Pulmonary Embolism 5.3%
Platelet Count Decreased 4.0%
Sepsis 3.7%
Urinary Tract Infection 3.6%
Death 3.3%
Pleural Effusion 3.2%
Renal Failure Chronic 3.1%
Weight Decreased 2.9%
C-reactive Protein Increased 2.8%
Pancreatic Carcinoma 2.7%
Rash 2.7%
Anaemia 2.4%
Neutrophil Count Decreased 2.4%
Renal Failure Acute 2.3%
Concomitant
Breast Cancer 12.9%
Product Used For Unknown Indication 12.8%
Metastases To Bone 12.1%
Breast Cancer Metastatic 11.0%
Drug Use For Unknown Indication 6.0%
Pancreatic Carcinoma 4.9%
Chemotherapy 4.3%
Pain 4.1%
Prophylaxis 4.0%
Nausea 3.5%
Non-small Cell Lung Cancer 3.4%
Depression 3.1%
Premedication 2.9%
Ovarian Cancer 2.8%
Cancer Pain 2.5%
Lung Neoplasm Malignant 2.4%
Hypercalcaemia 2.4%
Lung Adenocarcinoma 1.7%
Muscle Spasms 1.7%
Diabetes Mellitus 1.6%
Death 11.3%
Weight Decreased 10.8%
Vomiting 9.2%
Tooth Extraction 8.8%
Toothache 7.0%
Disease Progression 5.6%
Wheezing 5.3%
Thrombocytopenia 5.1%
Metastases To Liver 4.5%
Rash 4.0%
Wound Infection Staphylococcal 3.8%
Osteonecrosis 3.3%
White Blood Cell Count Decreased 3.0%
Pyrexia 2.9%
Pain 2.7%
Pneumonia 2.7%
Drug Ineffective 2.5%
Tooth Loss 2.5%
Weight Increased 2.5%
Platelet Count Decreased 2.4%
Interacting
Metabolic Syndrome 41.7%
Bile Duct Cancer 12.6%
Pancreatic Carcinoma 10.9%
Prophylaxis 10.3%
Arthritis 9.1%
Non-small Cell Lung Cancer 5.7%
Essential Thrombocythaemia 4.0%
Gout 3.4%
Ovarian Epithelial Cancer 1.7%
Cholangitis 0.6%
Rhabdomyolysis 25.0%
Weight Increased 22.5%
Sepsis 15.0%
Pancytopenia 12.5%
Drug Interaction 10.0%
Rash Erythematous 10.0%
Renal Failure Acute 5.0%